Gatta L et al. |
A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963079
|
Thijs JC et al. |
Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. |
1994 |
Aliment. Pharmacol. Ther. |
pmid:8186339
|
Kamada T et al. |
The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12869086
|
Logan RP et al. |
Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:8527618
|
Miehlke S et al. |
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16842467
|
Gisbert JP et al. |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10540045
|
Bruley Des Varannes S et al. |
There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472320
|
Nada T et al. |
DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298604
|
Adachi K et al. |
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472321
|
Kaneko F et al. |
High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298607
|
Masaoka T et al. |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298608
|
Kondo Y et al. |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15298609
|
Gschwantler M et al. |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468682
|
Paré P et al. |
Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468683
|
Sasaki A et al. |
Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823156
|
Fischbach LA et al. |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569109
|
Sung JJ et al. |
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726384
|
Pazzi P et al. |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726385
|
Azuma T et al. |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10807427
|
Talley NJ et al. |
Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678811
|
Ricciardiello L et al. |
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678812
|
Cammarota G et al. |
One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678813
|
Yousfi MM et al. |
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8853767
|
Georgopoulos SD et al. |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876712
|
Elizalde JI et al. |
Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876713
|
Hawkey CJ et al. |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12694089
|
Wong BC et al. |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11069326
|
Lionetti E et al. |
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17032283
|
Laurent J et al. |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11683693
|
Kashimura H et al. |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215732
|
Lee JM et al. |
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215733
|
You JH et al. |
Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421876
|
Gisbert JP and Calvet X |
Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:22017749
|
Pellegrini M et al. |
Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16098001
|
Pilotto A and Malfertheiner P |
Review article: an approach to Helicobacter pylori infection in the elderly. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11929385
|
Laine L et al. |
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354200
|
Rinaldi V et al. |
The management of failed dual or triple therapy for Helicobacter pylori eradication. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354202
|
Osato MS et al. |
Comparative efficacy of new investigational agents against Helicobacter pylori. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11284777
|
Xiao SD et al. |
A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11136281
|
Mason JM et al. |
Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18793340
|
Nista EC et al. |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969089
|
Peterson WL et al. |
Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791947
|
Delchier JC et al. |
Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791948
|
Isomoto H et al. |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848631
|
Miwa H et al. |
Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823158
|
Harris AW et al. |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971302
|
Moshkowitz M et al. |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971304
|
Savarino V et al. |
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886045
|
Wang WH et al. |
High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886046
|
Laine L et al. |
Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971306
|